Notable portfolio companies include Adaptive Phage Therapeutics, Vedanta Biosciences, and Venatorx Pharmaceuticals. AMR Action Fund is led by key partners who advocate for market reforms and policy solutions to enhance the societal value of lifesaving drugs. They offer unique value-add services by building partnerships to foster a sustainable innovation ecosystem, ensuring continuous evolution of treatments alongside the threat of antimicrobial resistance (AMR).
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies3
Follow-on Investments1
Current Portfolio Count2
AMR Action Fund
AMR Action Fund focuses on investing in biotechnology companies that are developing treatments for life-threatening antimicrobial-resistant infections. Their investment strategy includes participating in Series B, Series C, and Series E funding rounds, with the goal of launching two to four new antimicrobials over the next decade. The fund also emphasizes creating a sustainable investment environment for these critical pathogen therapies.
Total Portfolio Exits1
Top Investment Stages
Series B2 (50.0%)
Series C1 (25.0%)
Series E1 (25.0%)
Stage Mix
Series B 50%Series C 25%Series E 25%
Concentration shown as share of disclosed investments by stage.
